Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Pre-market Movers For Dec 7 (NFLX, ACRX, AMRN, AVGO, ZGNX)

RELATED NEWS
Trade NFLX now with 

Gainers:

AcelRx Pharmaceuticals, Inc. (ACRX: Quote) is rising 5 percent to $3.48. The company announced that it has priced its underwritten public offering of 12.5 million common shares at $3.31 per share.

Decliners:

Netflix, Inc. (NFLX: Quote) is down 0.36 percent to $85.86. Netflix disclosed that the company and its chief executive Reed Hastings each received a Wells Notice from SEC Staff about its intent to recommend to the SEC to bring a civil action for violations of fair disclosure related to statement he posted in Facebook in July about the 1 billion hour service usage.

Amarin Corporation plc (AMRN: Quote) is plunging 19 percent to $9.71. The company announced $100 million non-equity financing through a hybrid debt-like instrument. The company also noted that it is continuing to assess strategic options.

Avago Technologies Ltd. (AVGO: Quote) is falling over 2 percent to $34.30. The company announced the sale of 21.49 million ordinary shares by certain existing shareholders, including its President and chief executive and entities affiliated with certain directors.

Trading halt:

Trading in shares of Zogenix, Inc. (ZGNX: Quote) was halted.

Click here to receive FREE breaking news email alerts for Netflix Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
A Thai company has bought iconic U.S. tuna brand Bumble Bee for $1.51 billion dollars. Thai Union Frozen Products Public Company Limited or TUF, the world's largest processor of shelf-stable tuna products snapped up Bumble Bee from private equity firm Lion Capital. Post Synergies, the transaction... Here is a list of interesting stocks to watch on December 19. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed below and many more have been researched already, and... Shares of OvaScience Inc. (OVAS) have had a strong run in 2014, rising over 370 percent year-to-date. And that's indeed a very impressive return delivered by the fertility treatment company, which suffered a setback last year when it had to suspend a U.S. trial of its flagship fertility treatment due to regulatory concerns raised by the FDA.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.